376270 — HEM Pharma Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeSmall CapMomentum Trap

Annual income statement for HEM Pharma, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	PROSPECTUS	PROSPECTUS	PROSPECTUS	Annual Audited Accounts	ARS
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	1,857	3,668	5,344	15,067	12,979
Cost of Revenue
Gross Profit	487	623	801	1,622	632
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	12,812	16,911	17,110	22,754	28,561
Operating Profit	-10,955	-13,243	-11,766	-7,687	-15,582
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-10,919	-13,009	-11,667	-7,611	-23,720
Provision for Income Taxes
Net Income After Taxes	-10,919	-13,009	-11,667	-7,646	-23,724
Minority Interest
Net Income Before Extraordinary Items
Net Income	-10,919	-13,009	-11,667	-7,646	-23,842
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	-10,919	-13,009	-11,667	-7,646	-23,842
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-1,571	-1,871	-1,638	-1,099	-3,389
Dividends per Share